A possible role for metalloproteinases in renal cyst development

American Journal of Physiology - Renal Physiology

Volumn 280, Issue 3 49-3, 2001, Pages

  Obermüller, Nicholas ^a   Morente, Natividad ^a   Kränzlin, Bettina ^a   Gretz, Norbert ^a   Witzgall, Ralph ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autosomal dominant polycystic kidney disease; Extracellular matrix; Matrix metalloproteinase 14; Therapy; Tissue inhibitor of metalloproteinases 2; Transforming growth factor 2

Indexed keywords

BATIMASTAT; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; ENZYME METABOLISM; EXTRACELLULAR MATRIX; HUMAN; KIDNEY CYST; KIDNEY POLYCYSTIC DISEASE; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0034980706     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.2001.280.3.f540     Document Type: Article

References (83)

1. Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level
2. Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease
3. Renal remodelling in dietary protein modified rat polycystic kidney disease
4. Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites
5. Recent advances in matrix metalloproteinase inhibitor research
6. Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix
7. Proteolytic remodeling of extracellular matrix
8. Transforming growth factor β in tissue fibrosis
9. Matrix metalloproteinase inhibitors in the treatment of cancer
10. Polycystic kidney disease: Primary extracellular matrix abnormality or defective cellular differentiation
11. Biology of polycystic kidney disease
12. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
13. Prognosis of adult onset polycystic kidney disease re-evaluated
14. Modification of disease progression in rats with inherited polycystic kidney disease
15. Autosomal-dominant polycystic kidney disease in the rat
16. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats
17. Metalloprotease-mediated ligand release regulates autocrine signaling through the epidermal growth factor receptor
18. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor
19. Membrane associated matrix metalloproteinases in metastasis
20. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation
21. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease
22. Cytokines in fluids from polycystic kidneys
23. Methylprednisolone retards the progression of inherited polycystic kidney disease in rodents
24. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat
25. Gender-dependent disease severity in autosomal polycystic kidney disease of rats
26. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover
27. Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3
28. Unaltered secretion of β-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice
29. Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in Madin-Darby canine kidney epithelial cells
30. Role of membrane-type matrix metalloproteinase 1 (MT-1-MMP), MMP-2, and its inhibitor in nephrogenesis
31. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats
32. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells
33. Azotemia and extrarenal manifestations in old female Han:SPRD (cy/+) rats
34. Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro
35. The effect of paclitaxel on the progression of polycystic kidney disease in rodents
36. Matrix metalloproteinases: Structures, evolution, and diversification
37. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein
38. Effect of probucol in a murine model of slowly progressive polycystic kidney disease
39. Matrix metalloproteinases
40. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease
41. Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis
42. The swelling-activated chloride channel ClC-2, the chloride channel ClC-3, and ClC-5, a chloride channel mutated in kidney stone disease, are expressed in distinct subpopulations of renal epithelial cells
43. Differentiation and cell polarity during renal cyst formation in the Han:SPRD (cy/+) rat, a model for ADPKD
44. Soy protein modification of rat polycystic kidney disease
45. Flaxseed ameliorates interstitial nephritis in rat polycystic kidney disease
46. Modification of polycystic kidney disease and fatty acid status by soy protein diet
47. Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat
48. Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease
49. Progressive renal fibrosis in murine polycystic kidney disease: An immunohistochemical observation
50. Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor
51. The diagnosis and prognosis of autosomal dominant polycystic kidney disease
52. Immunohistochemical localization of TGFβ1, TGFβ2, and TGFβ3 in the mouse embryo: Expression patterns suggest multiple roles during embryonic development
53. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF
54. Matrix metalloproteinase-2 in a murine model of infantile-type polycystic kidney disease
55. Matrix metalloproteinases and TIMPs in cultured C57BL/6J-cpk kidney tubules
56. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease
57. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease
58. Transforming growth factor-β selectively inhibits branching morphogenesis but not tubulogenesis
59. TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes
60. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat
61. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease
62. Differential expression of TGF β1, β2 and β 3 genes during mouse embryogenesis
63. Presence of laminin fragments in cyst fluid from patients with autosomal dominant polycystic kidney disease (ADPKD): Role in proliferation of tubular epithelial cells
64. Efficacy of taxol in the orpk mouse model of polycystic kidney disease
65. Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease
66. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor
67. In vitro modulation of cyst formation by a novel tyrosine kinase inhibitor
68. Release of transforming growth factor-β 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin
69. Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease
70. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis
71. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16
72. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease
73. Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease
74. Renal cystic disease and ammoniagenesis in Han:SPRD rats
75. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
76. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
77. Epithelial cell polarity and disease
78. Matrix metalloproteinase inhibitors
79. Taxol inhibits progression of congenital polycystic kidney disease
80. Microtubule active taxanes inhibit polycystic disease progression in cpk mice
81. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocket
82. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I